Patient selection for transcatheter aortic valve implantation: An interventional cardiology perspective

Darrren Mylotte¹, Giuseppe Martucci², Nicolo Piazza³⁴

¹Department of Interventional Cardiology at McGill University Health Centre (MUHC), Montreal, Canada; ²Department of Interventional Cardiology at McGill University Health Centre (MUHC), Montreal, Quebec; ³Department of Interventional Cardiology at McGill University Health Centre (MUHC), Montreal, Quebec, Canada; ⁴Department of Cardiac Surgery at German Heart Center Munich, Munich, Germany

Corresponding to: Nicolo Piazza, MD, PhD, FRCPC, FESC. Department of Interventional Cardiology, McGill University Health Centre, Royal Victoria Hospital, 687 Pine Avenue, H3A 1A1, Montreal, Quebec, Canada. Email: nicolopiazza@mac.com.

Abstract: Transcatheter aortic valve implantation (TAVI) has emerged as a highly effective minimally invasive treatment symptomatic for severe calcific aortic stenosis in patients at high or prohibitive surgical risk. The success of TAVI has been determined by a number of factors, but in particular by appropriate patient selection. Appropriate patient selection involves identifying patients with the potential to benefit most from TAVI and individualizing the bioprosthesis type and size, and the vascular access site for each case. We present herein, our critical appraisal on patient selection for TAVI: an interventional cardiology perspective.

Key Words: Aortic stenosis; transcatheter heart valve; transcatheter aortic valve implantation; TAVI; Edwards SAPIEN; Medtronic CoreValve; patient selection

Submitted May 21. Accepted for publication Jun 18, 2012.
DOI: 10.3978/j.issn.2225-319X.2012.06.08

Introduction

In April 2002, Alain Cribier performed the first-in-human transcatheter aortic valve implantation (TAVI). In the ensuing decade, this novel technique has evolved into a relatively mature widely accepted treatment for high or prohibitive surgical risk patients with symptomatic severe calcific aortic stenosis (AS) requiring aortic valve replacement (AVR). The Edwards SAPIEN transcatheter heart valve (THV) (Edwards LifeSciences, Irvine, CA) (Figure 1) and Medtronic CoreValve (Medtronic, Minneapolis, MN) (Figure 2) are licensed in Europe for implantation in selected patients, and in excess of 80,000 patients worldwide have undergone TAVI.

Careful, considered patient selection by a team of experienced interventional cardiologists, cardiac surgeons, anaesthetists, and imaging specialists (the heart team) has been at the core of the TAVI success story (1). Patient selection for TAVI continues to evolve however, as the almost daily publication of TAVI-related data defines and refines the patient, anatomical, and procedural factors that determine successful implantation. Put simply, appropriate patient selection implies identifying candidates who benefit most from TAVI, however, this can be a complex process (Table 1).

TAVI eligibility

Potential TAVI recipients must satisfy three essential criteria in order to be deemed “TAVI-eligible” (2,3): severe symptomatic AS, high or prohibitive surgical risk, and absence of contraindications to TAVI.

Confirmation of the severity of aortic stenosis

Transcatheter aortic valve implantation is indicated for selected patients with severe AS, thus confirmation of the AS severity is mandatory in all cases. Echocardiography is the gold standard method to assess AS, and yields both...
important anatomic and haemodynamic information. Doppler evaluation of the peak and mean transaortic gradients and determination of the aortic valve area (AVA) by the continuity equation are recommended. Current societal guidelines define severe AS as a mean aortic valve gradient of ≥40 mmHg or an AVA of ≤1 cm² (<0.6 cm²/m²) (3,4). In patients with low transaortic gradients, despite an AVA consistent with severe AS, dobutamine stress echocardiography is recommended to distinguish between severe and pseudo-severe AS (5). The presence of symptoms is used to guide management of AS patients, however determining the nature of symptoms is not always straightforward. In cases of equivocal symptoms, exercise stress testing, and in particular stress echocardiography are advised (6).

**Surgical risk eligibility**

Transcatheter aortic valve implantation is indicated for selected patients at high or prohibitive surgical risk. Thus, the advent of TAVI has renewed interest in the use of surgical risk algorithms. Surgical risk has been quantified using the logistic European System for Cardiac Operative Risk Evaluation (EuroSCORE) (7) and the Society of Thoracic Surgeons (STS) Predicted Risk of Mortality score (8). However, these scores share important limitations in high-risk patient subsets, most notably a limited predictive capacity and an inability to capture significant comorbid conditions in what is a heterogeneous patient group. The logistic EuroSCORE, for example, has a low discriminatory power in TAVI patients (C statistics 0.61 to 0.64) (9). As such, the applicability of these scores in patient selection for TAVI has been questioned (10-12). Despite these limitations, patient enrolment in TAVI trials has been determined by a EuroSCORE >15% or an STS score >10% (13-15). However, a number of comorbid illnesses associated with adverse surgical outcomes are not included in these risk calculation scores, including: chronic lung disease [forced expiratory volume in 1 second (FEV1) <1 litre]; liver cirrhosis (Child class A or B); pulmonary hypertension (pulmonary artery systolic pressure >60 mmHg); previous cardiac surgery; porcelain aorta; recurrent pulmonary emboli; right ventricular failure; contraindication to traditional open chest surgery (wide beam radiotherapy); or cachexia (body mass index <18 kg/m²).

As such, we recommend these scores be used as a guide for patient selection, though they should not supersede clinical judgement.
Anatomical eligibility

Transcatheter aortic valve implantation is indicated for patients with severe AS who meet certain anatomical criteria, and the bioprosthesis type, size and mode of delivery are entirely reliant on pre-procedural anatomical screening. Multimodality imaging using echocardiography, multidetector computed tomography (MDCT) and fluoroscopy/angiography are used for detailed anatomical screening (16).

Vascular screening

Evaluation of the peripheral vasculature necessitates assessment of 3 important features: the size (minimal luminal diameter), tortuosity, and calcification of the iliofemoral arteries. Vascular assessment is most commonly performed using contrast angiography or MDCT (17).

Using contrast angiography, a SFAR ratio $\geq 1.05$ (outer Sheath diameter to Femoral Artery minimal luminal diameter Ratio) has been identified as a predictor of valve

---

### Table 1 Pre-procedure screening recommendations

<table>
<thead>
<tr>
<th>Category</th>
<th>Evaluation</th>
</tr>
</thead>
<tbody>
<tr>
<td>Laboratory indices</td>
<td>Full blood count, serum urea, creatinine and electrolytes, C-reactive protein, serum transaminases, serum albumin, coagulation profile, blood culture, sputum culture, mid-stream urine, glycosylated haemoglobin, human immunodeficiency virus, hepatitis serology</td>
</tr>
<tr>
<td>Physical indices</td>
<td>Height, weight, body mass index</td>
</tr>
<tr>
<td>Clinical data to calculate logistic EuroSCORE or STS score</td>
<td>Detailed clinical history, examination and current medication list, 12 lead electrocardiography, echocardiography (transthoracic/transoesophageal), coronary angiography, peripheral vascular screening (contrast angiography/multidetector computed tomography), pulmonary function testing, right heart catheterization</td>
</tr>
<tr>
<td>Clinical parameters of comorbid conditions</td>
<td>Pulmonary function tests, carotid, vertebral and abdominal ultrasonography</td>
</tr>
<tr>
<td>Fragility and cognitive function*</td>
<td>Grip strength, graded exercise testing, walk test, physical activity level, mini-mental score</td>
</tr>
<tr>
<td>Confirmation of aortic stenosis severity and assessment of associated pathology</td>
<td>Echocardiography (transthoracic/transoesophageal), exercise stress testing, stress echocardiography</td>
</tr>
<tr>
<td>Procedural planning</td>
<td>Multidetector computed tomography/transoesophageal echocardiography</td>
</tr>
</tbody>
</table>

Legend: STS = Society of Thoracic Surgeons; * = Elements of the fried frailty index
academic research consortium (VARC) major vascular complications and 30-day mortality (18). This ratio decreases to 1.00 in non-calcified vessels and increases to 1.10 in the presence of moderate to severe calcification.

MDCT is probably the gold standard test for screening the peripheral vasculature of potential TAVI recipients (Figure 3) (19). With MDCT, assessment of vessel tortuosity, calcification, and vessel size, is enhanced compared to contrast angiography; MDCT, however, is associated with increased iodinated contrast exposure. High-pitch spiral dual source CT with minimized contrast volume may overcome this limitation (20).

**Annulus assessment**

Although not a distinct anatomic structure, the aortic valve annulus may be defined as the virtual ring formed at the junction of the basal attachment points of the aortic valve leaflets within the left ventricle (21). In this plane, the oval aortic annulus represents the transition point between the left ventricular outflow tract and the aortic root. Accurate measurement of the aortic annulus diameter is of critical importance for THV sizing and the short- and long-term success of the procedure. Valve oversizing risks catastrophic annulus rupture, while undersizing may result in valve migration or paravalvular regurgitation; which has been recognized as an independent predictor of long-term mortality (22).

Transthoracic echocardiography (TTE), transesophageal echocardiography (TEE), MDCT, contrast aortography, and magnetic resonance imaging (MRI) can all be used to assess the annulus dimensions. Although much debate surrounds the choice of imaging modality for optimal measurement of the non-circular annulus for the purposes of TAVI, MDCT is becoming recognized as the gold standard.

Although TEE is the most practical imaging modality, 2-dimensional (D) measurements of the 3-D aortic annulus,
can lead to underestimation of the true dimensions of the annulus (23). It has been suggested that echocardiographic measurement of the annulus potentially results in valve undersizing, and consequently increases the risk of paravalvular aortic regurgitation (24). A recent publication noted that 3-D TEE may provide more accurate aortic annular measurements than 2-D TEE (25), however the use of 3-D TEE is not yet endorsed by societal guidelines (26).

MDCT reconstruction of the annulus orthogonal to the center-axis of the left ventricular outflow tract allows for the assessment of minimal and maximal diameter, circumference, and area measurements. MDCT data has confirmed that the majority of aortic annuli are oval, and has shown the mean difference between the maximum and minimum diameter of the aortic annulus to be 6.5 mm (95% confidence interval, 5.7-7.2) (27). Assessment of the aortic valvar structure with MDCT also facilitates assessment of cusp morphology, and the distribution of calcification. In the light of these advantages, MDCT is becoming the default imaging modality to assess aortic annular dimensions. It remains unclear how to exactly apply MDCT-based valve sizing to existing echocardiographic sizing criteria (27) - this will be further discussed below.

**Contraindications to TAVI**

Although many elderly patients with severe AS meet the “inclusion” criteria for TAVI, these procedures are not suitable for all. As the technology and physician experience evolves, some initial contraindications have been discounted, while others have emerged.

Recently, it has been recognised that frailty and futility are important concepts when selecting patients for TAVI. Frailty is considered to be a distinct clinical syndrome characterized by decreasing muscle mass, energy expenditure, and malnutrition, and imparts extreme vulnerability to adverse events (28). Futility implies that a patients’ condition is so advanced, that meaningful improvement will not be achieved despite a technically successful intervention. In this regard, the 2-year results of the Partner trials offer much food for thought. In inoperable patients (cohort B), two-year mortality following TAVI was 43.3%, the majority of whom died from cardiovascular causes (64.9%) (29). Similarly, two-year mortality was 33.9% in high operative risk patients that received TAVI in Partner cohort A (22). These data send a clear message: performing TAVI on patients who derive little long-term benefit due to irreversible coexisting conditions should be avoided, particularly in the current resource-limited environment. Preliminary analyses suggest that patients with lower surgical risk scores (EuroSCORE, STS) derive the most benefit from TAVI (29,30), though further analysis of large patient populations is required before using risk score cut-off-points to define TAVI-ineligible patients. The role of specific risk scores to assess frailty, such as the Fried Frailty Index (28), is yet to be determined.

In borderline cases, where the decision to proceed to TAVI is not clear due to advanced age, co-morbid conditions or other factors, percutaneous balloon aortic valvuloplasty (BAV) can represent a useful additional selection tool (31). BAV strategy is associated with rapid functional improvement and thus, enhances the prediction of very frail patients who might benefit from TAVI, without incurring the risk or cost associated with a full TAVI procedure. In one study, re-evaluation of borderline patients 30-days after BAV, deemed 46% TAVI eligible, 28% surgical AVR eligible, while 21% demonstrated no functional improvement and were therefore assigned to medical therapy (31).

**Procedural considerations**

Careful planning of the TAVI procedure itself is a critical component of the patient selection process. The vascular access site and the bioprosthesis type and size are crucial to procedural success.

**Vascular access**

Selection of the vascular access site is based on careful pre-procedural screening and should be individualized for each patient. Our preference is to select the least invasive route possible for TAVI. As such, all patients are evaluated for the feasibility of a transfemoral approach, and an alternative approach is only selected in the setting of a prohibitively small or diseased iliofemoral arterial system, the presence of mobile plaque, excessive calcification, or extreme tortuosity of the descending thoracic aorta. Alternative approaches in our order of preference are: subclavian (32-41); transaortic (42-48); and transapical (49-52). Importantly, we do not push the limits of the available technology and if the peripheral vasculature is unfavourable, an alternative access is selected. Feasibility does not equal safety.

The femoral artery is considered to be default vascular access site for TAVI. Theoretical advantages of the transfemoral approach include avoidance of general
General anaesthesia, thoracotomy, incision of the apex of the left ventricle, and potential complications such as delayed wound healing. Advantages to the non-transfemoral approaches include avoidance of peripheral vascular (except subclavian) and aortic complications. Importantly, the risk of periprocedural cerebral embolization and stroke appears to be similar between these different strategies (53,54).

To date, few studies have directly compared clinical outcomes between transfemoral and non-transfemoral TAVI (14,53,55,56). Compared to the femoral approach, non-transfemoral approaches (largely transapical) tends to be performed on higher risk patients, as assessed by EuroSCORE (largely driven by peripheral arterial disease). Transfemoral TAVI is associated with an increased risk of vascular complications, while non-transfemoral procedures have a higher risk of bleeding and surgical conversion (14,53). To date, non-transfemoral TAVI has been associated with increased 30-day and two-year mortality (14,53). Although this mortality difference may be due to the more advanced risk profile of the non-transfemoral patients, it is possible that these procedures themselves confer increased risk. General anaesthesia, thoracotomy, incision of the left ventricular apex and manipulation of a large catheter within the left ventricle are not without risk. However, it must be stated that as surgical experience with these devices improves, and dedicated transapical and transaortic devices are developed, improved outcomes are emerging with non-transfemoral TAVI (57). The advent of the transaortic approach is a particularly encouraging technique that avoids many of the theoretical complications associated with transapical TAVI (42-48).

**Bioprosthesis type and size**

Currently, two THV systems are available for implantation in Europe. The Edwards SAPIEN XT THV is a balloon-expandable valve that consists of a radiopaque cobalt-chromium frame, trileaflet bovine pericardial leaflets, and a polyethylene terephthalate fabric skirt. The Edwards SAPIEN XT THV is currently available in 4 sizes (20, 23, 26, and 29 mm) and can be implanted in native annuli with diameters of 16 to 27 mm. The Medtronic CoreValve bioprosthesis is a self-expandable valve manufactured from a radiopaque nitinol support frame, trileaflet porcine pericardial leaflets, and porcine pericardium fabric skirt. The CoreValve is available in 4 sizes (23, 26, 29, and 31 mm) and can be implanted in native annuli with diameters ranging from 17 to 29 mm.

Comparisons between the two available bioprosthesis types are few (58,59). To date, appreciable differences between the systems include a higher incidence of new pacemaker requirement with the CoreValve device (53). Approximately 15-47% (60-62) and 4-21% (63,64) of patients require a new permanent pacemaker after CoreValve and Edwards SAPIEN implantation, respectively. Importantly, new pacemaker implantation does not appear to be associated with long-term mortality (65). Therefore, the decision to implant a particular bioprosthesis depends largely on the availability of the devices, the experience of the operator with each device, and pre-procedural anatomical screening.

Operator experience is an important factor in determining TAVI outcomes (66-68). Therefore, the majority of individual operators tend to implant a single bioprosthesis type while many high volume TAVI centres implant both valves. In these centres, bioprosthesis choice is dependant on the preprocedural assessment of the peripheral vasculature and the aortic annulus.

Manufacture sizing guidelines, based on echocardiographic annulus measurement, are available (69). For the Edwards Sapien XT valve, the 20 mm valve is designed for small annuli between 16-19 mm, the 23 mm valve is designed for 18-21 mm annuli, the 26 mm valve for 22-25 mm annuli, and the larger 29 mm valve for 25-27 mm annuli. For the Medtronic CoreValve 23, 26, 29, and 31 mm bioprosthesis sizes are designed for annuli between 17-20, 20-23, 24-27, and 26-29 mm respectively.

**Personal perspective on transcatheter aortic valve sizing**

Appropriate oversizing of transcatheter aortic valves relative to the aortic annulus is needed for (I) anchoring to prevent migration; (II) sealing to prevent paravalvular aortic regurgitation; and (III) proper valve functioning to prevent patient-prosthesis mismatch. Current echocardiographic sizing guidelines for the Medtronic CoreValve and Edwards SAPIEN XT would suggest an oversizing percentage between 7-30% and 4-27%, respectively (Table 2). Because self-expanding and balloon-expandable valves interfere differently with the aortic annulus, we should not expect similar oversizing principles. In our practice, MDCT dictates selection of the transcatheter aortic valve size. We compare the ratio of the aortic annulus perimeter obtained by MDCT to the perimeter of the transcatheter aortic valve (i.e. perimeter of the transcatheter aortic valve minus the
perimeter of the aortic annulus then divided by the perimeter of the aortic annulus multiplied by 100). For self-expanding and balloon-expanding prostheses we aim for an oversizing percentage of 8-20% and 5-15%, respectively. Knowing that echocardiography underestimates the aortic annulus measurements, the actual oversizing obtained by echocardiography is less than expected. We believe that MDCT sizing allows a better approximation between the expected and actual oversizing than echocardiography.

Finally, the choice of bioprosthesis can be influenced by the iliofemoral anatomy. The minimal femoral dimensions for the available TAVI systems are based on the French (Fr) size of the access sheaths and catheters. According to manufacture guidelines, the 18 Fr CoreValve and 22/24 Fr Edwards SAPIEN delivery sheaths require 6 mm, 7 and 8 mm diameter femoral arteries respectively. The newer Edwards SAPIEN XT system requires 6 mm and 6.5 mm femoral artery diameters for the 18 Fr and 19 Fr systems respectively.

### Future perspectives

It is likely that, similar to the evolution of drug-eluting stents, an initial conservative approach during the TAVI regulatory approval process will be followed by off-label case selection and treatment of lower risk patients. The move towards treating lower risk patients has already emerged in Europe (70,71). Future trials such as SURTAVI and Partner 2 will explore TAVI in patients at intermediate operative risk.

Although risk scores continue to play an important role in guiding patient selection for TAVI, they are poorly suited to this task. The development of alternative risk models designed specifically for high-risk TAVI recipients (72), and perhaps incorporating a measure of frailty, are required. Furthermore, the integration of MDCT in peripheral screening and most importantly, in annulus measurement for bioprosthesis sizing, is likely to improve outcomes in TAVI recipients.

### Conclusions

Patient selection for TAVI is of considerable importance in optimizing procedural and long-term outcomes. The multi-disciplinary heart team approach, and the use of multimodal imaging is strongly advocated. Annulus sizing using MDCT is emerging as the modality of choice for assessment of annulus size and bioprosthesis sizing. Surgical risk scores must be refined to represent the unique challenge posed by high-risk TAVI populations, and incorporate a measure of frailty.

### Acknowledgements

Disclosure: Dr Piazza is a consultant for Medtronic.

### References

4. Bonow RO, Carabello BA, Chatterjee K, et al. 2008 Focused update incorporated into the ACC/AHA 2006...
53. Moat NE, Ludman P, de Belder MA, et al. Long-Term Outcomes After Transcatheter Aortic Valve Implantation in High-Risk Patients With Severe Aortic Stenosis: The


